Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 15;4(4):FSO289.
doi: 10.4155/fsoa-2017-0149. eCollection 2018 Apr.

Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis

Enrique R Soriano  1   1 , Analia Dellepiane  2   2 , Gabriela Salvatierra  3   3 , Cristian Alejandro Benítez  4   4 , Rodrigo Garcia Salinas  5   5 , Carlos Baruzzo  6   6
Affiliations

Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis

Enrique R Soriano et al. Future Sci OA. .

Abstract

Aim: To determine the efficacy and safety of certolizumab pegol for the treatment of rheumatoid arthritis in a real-world setting.

Materials & methods: Patients with moderate-to-severe rheumatoid arthritis who initiated therapy with certolizumab were followed for 12 weeks. Response was assessed with Disease Activity Score of 28 joints, European Ligue Against Rheumatism criteria and Simplified Disease Activity Index. Predictors of response were analyzed with binary logistic regression models.

Results: Statistically significant decreases in tender and swollen joint counts, laboratory parameters and use of corticosteroids and disease-modifying antirheumatic drugs were found. Disease activity also significantly diminished. Higher Disease Activity Score of 28 joints at baseline was the main predictor of response. No severe adverse events were reported.

Conclusion: Certolizumab was effective and well tolerated, particularly in the subpopulation with higher inflammatory burden at baseline.

Keywords: anti-TNFα agent; certolizumab; rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure The authors have received grants from UCB and Laboratories Montpellier for completing the study. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. The authors thank Content Ed Net (Madrid, Spain) for writing and editorial assistance, which was funded by UCB and Laboratories Montpellier.

References

    1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 2011;365:2205–2219. - PubMed
    1. Scott DL, Wolfe F, Huizinga TWJ, et al. Rheumatoid arthritis. Lancet. 2010;376:1094–1108. - PubMed
    1. Sanmartí R, García-Rodríguez S, Álvaro-Gracia JM, et al. 2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis. Reumatol. Clin. 2015;11:279–294. - PubMed
    1. Grupo de estudio de Artritis Reumatoidea. Buenos Aires; Argentina: 2013. Update of the clinical practice guidelines on rheumatoid arthritis management, Sociedad Argentina de Reumatología.
    1. Goel N, Stephens S. Certolizumab pegol. MAbs. 2010;2:137–147. - PMC - PubMed

LinkOut - more resources